Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $433 to $400.